The FDA has delayed its decision to approve a new treatment for hereditary angioedema, citing a heavy workload and limited resources.
The drug, sebetralstat, developed by Kalvista Pharmaceuticals, was scheduled for a decision by June 17 under the Prescription Drug User Fee Act timeline, according to a June 13 news release from the drugmaker.
The FDA informed KalVista on June 13 that it would miss the target date but expects to issue a decision within four weeks. The company stated it is continuing to work with the FDA and expects a near-term approval.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
